RXi Pharmaceuticals names Noah Beerman president and CEO
RXi Pharmaceuticals names Noah Beerman president and CEO
6 November 2009 - US discovery-stage biopharmaceutical company RXi Pharmaceuticals Corporation (NASDAQ: RXII) said today it has appointed Noah Beerman as president and chief executive officer.
Beerman succeeds the company's co-founder, Tod Woolf, who will continue as a member of RXi's scientific advisory board.
Most recently, Beerman served as executive VP, chief business officer for Indevus Pharmaceuticals Inc, which was acquired by Endo Pharmaceuticals in March 2009.
Prior to joining Indevus in 1997, Beerman was VP responsible for health care at Technology Management and Funding (TMF), a venture firm. Earlier in his career, he served in a variety of business and scientific capacities at Creative BioMolecules, Sandoz AG, and Repligen.
((Comments on this story may be sent to This e-mail address is being protected from spambots. You need JavaScript enabled to view it ))
| Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2010 Financial Results on Tuesday, November 10th, at 4:30 P.M. EST< Prev | Next >Cytokinetics adds Pat Gage to board of directors |
|---|
Main Menu
FREE Daily Update!
